Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACB Aurora Cannabis	$5.50 +0.2%	$4.58	$3.42 ▼ $7.20	$309.18M	1.94	1.55 million shs	853,574 shs
CMPX Compass Therapeutics	$2.09 -0.5%	$1.91	$0.77 ▼ $4.08	$289.01M	1.4	923,887 shs	529,883 shs
HRTX Heron Therapeutics	$1.85 -1.1%	$2.09	$1.04 ▼ $3.93	$282.24M	1.33	2.28 million shs	780,850 shs
ZURA Zura Bio	$1.02 -1.9%	$1.25	$0.97 ▼ $5.56	$69.74M	0.05	410,534 shs	293,130 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACB Aurora Cannabis	0.00%	+7.21%	+16.77%	-6.62%	-19.71%
CMPX Compass Therapeutics	0.00%	-0.48%	-1.42%	-28.42%	+33.97%
HRTX Heron Therapeutics	0.00%	-6.09%	-18.50%	+6.94%	-46.69%
ZURA Zura Bio	0.00%	-8.11%	-29.17%	-27.14%	-81.52%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACB Aurora Cannabis	0.7458 of 5 stars	0.0	2.0	0.0	3.8	0.8	0.6
CMPX Compass Therapeutics	3.8824 of 5 stars	4.6	3.0	0.0	3.0	5.0	0.0
HRTX Heron Therapeutics	3.7036 of 5 stars	3.5	0.0	4.2	3.6	1.7	0.6
ZURA Zura Bio	2.5512 of 5 stars	3.6	2.0	0.0	2.7	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACB Aurora Cannabis	3.67	Strong Buy	N/A	N/A
CMPX Compass Therapeutics	3.11	Buy	$13.13	527.99% Upside
HRTX Heron Therapeutics	3.00	Buy	$5.50	197.30% Upside
ZURA Zura Bio	3.13	Buy	$14.33	1,305.23% Upside

Current Analyst Ratings Breakdown

Latest ZURA, HRTX, CMPX, and ACB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/9/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
5/9/2025	ZURA Zura Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$19.00 ➝ $17.00
4/28/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
4/22/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/21/2025	CMPX Compass Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00
4/21/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
4/11/2025	HRTX Heron Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
4/4/2025	CMPX Compass Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $24.00
4/3/2025	ZURA Zura Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/3/2025	ZURA Zura Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $3.00
4/2/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00

(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACB Aurora Cannabis	$320.81M	0.96	$0.21 per share	26.35	$8.18 per share	0.67
CMPX Compass Therapeutics	$850K	340.01	N/A	N/A	$1.17 per share	1.79
HRTX Heron Therapeutics	$148.52M	1.90	N/A	N/A	($0.23) per share	-8.04
ZURA Zura Bio	N/A	N/A	N/A	N/A	$1.85 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACB Aurora Cannabis	-$48.62M	$0.05	110.02	12.50	N/A	0.42%	0.59%	0.42%	6/19/2025 (Estimated)
CMPX Compass Therapeutics	-$42.49M	-$0.41	N/A	N/A	N/A	N/A	-32.37%	-30.67%	8/11/2025 (Estimated)
HRTX Heron Therapeutics	-$110.56M	-$0.06	N/A	N/A	N/A	-20.31%	N/A	-12.72%	8/5/2025 (Estimated)
ZURA Zura Bio	-$69.24M	-$0.70	N/A	N/A	N/A	N/A	-37.36%	-29.81%	8/12/2025 (Estimated)

Latest ZURA, HRTX, CMPX, and ACB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/19/2025	Q4 2025	ACB Aurora Cannabis	$0.11	N/A	N/A	N/A	$88.85 million	N/A
5/8/2025	Q1 2025	CMPX Compass Therapeutics	-$0.12	-$0.12	N/A	-$0.12	N/A	N/A
5/8/2025	Q1 2025	ZURA Zura Bio	-$0.17	-$0.19	-$0.02	-$0.19	N/A	N/A
5/6/2025	Q1 2025	HRTX Heron Therapeutics	-$0.01	$0.01	+$0.02	$0.01	$37.08 million	$38.90 million
3/25/2025	Q4 2024	ZURA Zura Bio	-$0.17	-$0.08	+$0.09	-$0.08	N/A	$0.00 million
2/27/2025	Q4 2024	CMPX Compass Therapeutics	-$0.10	-$0.11	-$0.01	-$0.11	N/A	N/A
2/27/2025	Q4 2024	HRTX Heron Therapeutics	-$0.03	$0.02	+$0.05	$0.02	$37.37 million	$40.78 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACB Aurora Cannabis	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
HRTX Heron Therapeutics	N/A	N/A	N/A	N/A	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACB Aurora Cannabis	0.07	3.30	1.60
CMPX Compass Therapeutics	N/A	31.84	31.84
HRTX Heron Therapeutics	N/A	2.28	1.74
ZURA Zura Bio	N/A	10.36	10.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACB Aurora Cannabis	47.63%
CMPX Compass Therapeutics	68.43%
HRTX Heron Therapeutics	80.01%
ZURA Zura Bio	61.14%

Insider Ownership

Company	Insider Ownership
ACB Aurora Cannabis	0.01%
CMPX Compass Therapeutics	29.80%
HRTX Heron Therapeutics	5.86%
ZURA Zura Bio	14.23%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACB Aurora Cannabis	1,340	56.21 million	54.85 million	Optionable
CMPX Compass Therapeutics	20	138.28 million	98.38 million	Not Optionable
HRTX Heron Therapeutics	300	152.56 million	143.33 million	Optionable
ZURA Zura Bio	3	68.38 million	50.86 million	Optionable

ZURA, HRTX, CMPX, and ACB Headlines

Recent News About These Companies

Zura Bio shareholders approve board nominees and auditor

May 24 at 10:31 PM | investing.com

HC Wainwright Issues Positive Estimate for Zura Bio Earnings

May 23 at 7:49 AM | marketbeat.com

What is HC Wainwright's Forecast for Zura Bio Q2 Earnings?

May 23 at 1:39 AM | americanbankingnews.com

Q1 Earnings Estimate for Zura Bio Issued By HC Wainwright

May 22 at 7:07 AM | marketbeat.com

Zura Bio commences Phase II trial of tibulizumab for hidradenitis suppurativa

May 21, 2025 | msn.com

What is HC Wainwright's Forecast for Zura Bio Q1 Earnings?

May 21, 2025 | americanbankingnews.com

Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa

May 20, 2025 | businesswire.com

Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates

May 9, 2025 | standard-journal.com

Boxer Capital Management LLC Makes New Investment in Zura Bio Limited (NASDAQ:ZURA)

May 4, 2025 | marketbeat.com

Zura Bio (ZURA) Projected to Post Quarterly Earnings on Thursday

May 3, 2025 | marketbeat.com

Adage Capital Partners GP L.L.C. Buys Shares of 300,000 Zura Bio Limited (NASDAQ:ZURA)

May 2, 2025 | marketbeat.com

Zura Bio Limited (NASDAQ:ZURA) Receives Average Recommendation of "Buy" from Analysts

May 1, 2025 | marketbeat.com

Zura Bio Limited (NASDAQ:ZURA) Short Interest Down 51.8% in April

April 30, 2025 | marketbeat.com

After losing 56% in the past year, Zura Bio Limited (NASDAQ:ZURA) institutional owners must be relieved by the recent gain

April 24, 2025 | finance.yahoo.com

Zura Bio price target lowered to $3 from $5 at H.C. Wainwright

April 4, 2025 | markets.businessinsider.com

Zura Bio (ZURA) Gets a Buy from Guggenheim

March 31, 2025 | markets.businessinsider.com

Hopeful Week For Insiders Who Bought US$1.01m Of Zura Bio Stock

March 26, 2025 | finance.yahoo.com

Zura Bio Limited: 2024 Financial Results and Strategic Progress

March 26, 2025 | tipranks.com

Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

March 25, 2025 | businesswire.com

Zura Bio to Present at the Leerink Partners Global Healthcare Conference

February 24, 2025 | businesswire.com

ZURA stock touches 52-week low at $1.44 amid market shifts

February 11, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZURA, HRTX, CMPX, and ACB Company Descriptions

Aurora Cannabis NASDAQ:ACB

$5.50 +0.01 (+0.18%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$5.49 -0.01 (-0.18%)

As of 05/23/2025 07:55 PM Eastern

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Compass Therapeutics NASDAQ:CMPX

$2.09 -0.01 (-0.48%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$2.18 +0.10 (+4.55%)

As of 05/23/2025 07:52 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Heron Therapeutics NASDAQ:HRTX

$1.85 -0.02 (-1.07%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$1.83 -0.02 (-1.08%)

As of 05/23/2025 07:48 PM Eastern

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Zura Bio NASDAQ:ZURA

$1.02 -0.02 (-1.92%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$1.05 +0.03 (+2.84%)

As of 05/23/2025 04:19 PM Eastern

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time